NASDAQ Shariah screener · October 2026
Is Tempus AI, Inc. (TEM) Halal?
Tempus AI, Inc. · NASDAQ: TEM · Healthcare
The short answer
Tempus AI passes all three Shariah gates: it runs a permissible healthcare diagnostics and AI software business, carries $1.36B of interest-bearing debt (8.9% of its ~$15.35 billion market cap), and interest income of about 0.99% of revenue is well under the 5% ceiling. (Musaffa rates TEM not halal on its AAOIFI screen without stating the criterion — disclosed as a third-party disagreement.)
Gate 1 — Business activity: PASS
Gate 1 — business activity: PASS. Tempus AI, Inc. is a healthcare technology company building an AI-enabled precision-medicine platform ("Intelligent Diagnostics"). Per its FY2025 Form 10-K (Item 1, filed February 24, 2026), its two product lines are Diagnostics — genomic sequencing, PCR profiling and molecular pathology testing sold to healthcare providers, life sciences companies and researchers (about 75% of FY2025 revenue) — and Data and applications — licensing de-identified clinical, molecular and imaging data libraries plus analytics tools to pharmaceutical and biotech customers, including its Insights data product, Trials clinical-trial matching, and the Tempus One generative-AI assistant (about 25%).
The 10-K discloses no interest-based lending, alcohol, gambling, tobacco, pork or conventional insurance segments. The entire business is healthcare diagnostics, data licensing and AI software — the business passes gate 1.
Gate 2 — Debt and cash: PASS
Gate 2 — interest-bearing debt: PASS (8.9%, ceiling 33%). Per Tempus AI's Q2 2026 Form 10-Q condensed consolidated balance sheet (June 30, 2026), total interest-bearing debt was $1,360,710 thousand: convertible senior notes, net $1,172,781 thousand and convertible promissory notes $187,929 thousand. In the first half of 2026 the company repaid its $100 million revolving credit facility to zero and retired all other long-term debt. Operating lease liabilities ($12,192 thousand current plus $71,266 thousand noncurrent) are excluded — they are not interest-bearing debt.
$1.36 billion of interest-bearing debt against a market capitalization of about $15.35 billion (Finnhub, October 2, 2026) is 8.9%, well under the 33% ceiling. Cash and cash equivalents of $599,614 thousand plus marketable equity securities of $216,377 thousand at June 30, 2026 total about 5.3% of market cap.
Gate 3 — Non-compliant income: PASS
Gate 3 — non-compliant income: PASS (0.99%, ceiling 5%). Tempus AI's FY2025 Form 10-K discloses interest income as its own income-statement line: "Interest income" of $12,628 thousand in FY2025 (interest earned on cash and cash equivalents).
FY2025 interest income of $12,628 thousand against FY2025 total net revenue of $1,271,789 thousand is about 0.99%, well under the 5% ceiling. (For the first six months of 2026, interest income was $7,763 thousand per the Q2 2026 10-Q.)
Key figures used
- Business: AI-enabled precision-medicine platform - Diagnostics (~75% of FY2025 revenue: genomic sequencing, PCR profiling, molecular pathology) and Data and applications (~25%: de-identified data licensing, Insights, Trials matching, Tempus One AI assistant)
- Haram assessment: no interest-based lending; no alcohol/gambling/tobacco/pork/insurance segments disclosed — business passes gate 1
- Debt: $1,360,710K at Jun 30, 2026 (convertible senior notes $1,172,781K + convertible promissory notes $187,929K; revolver repaid to zero) — 8.9% of ~$15.35B market cap (Finnhub, Oct 2, 2026) - well under the 33% ceiling
- Cash: $599,614K cash and cash equivalents + $216,377K marketable equity securities at Jun 30, 2026 (~5.3% of market cap combined)
- Interest income: $12,628K in FY2025 (own income-statement line) vs $1,271,789K revenue = 0.99% - well under the 5% ceiling (H1 2026: $7,763K)
- Corporate actions: acquired Ambry Genetics Feb 2025 ($692.3M), Paige.AI and Deep 6 AI (2025); issued $750M 0.75% convertible senior notes due 2030 (Jul 2025); Personalis acquisition pending (S-4 filed Jul 2026)
- Market data: NASDAQ-listed (10-K cover confirms TEM / Nasdaq Stock Market LLC); still listed (confirmed October 2, 2026; live quotes, no delisting)
- Third-party: Musaffa rates TEM not halal (AAOIFI, Oct 2026) without stating the criterion — disclosed here as a third-party disagreement; Zoya's TEM page rating could not be determined; no ShariaPortfolio TEM page found
Frequently asked questions
What does Tempus AI do?
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company building an AI-enabled precision-medicine platform ('Intelligent Diagnostics'). Per its FY2025 Form 10-K it has two product lines: Diagnostics (about 75% of FY2025 revenue) - genomic sequencing, PCR profiling and molecular pathology testing sold to healthcare providers, life sciences companies and researchers; and Data and applications (about 25%) - licensing de-identified clinical, molecular and imaging data libraries plus analytics tools to pharmaceutical and biotech customers, including its Insights data product, Trials clinical-trial matching, and the Tempus One generative-AI assistant.
Is Tempus AI's business Shariah compliant?
Tempus AI's business is healthcare diagnostics, data licensing and AI software. Its FY2025 Form 10-K discloses no interest-based lending, alcohol, gambling, tobacco, pork or conventional insurance segments - the entire business is genomics testing, de-identified data licensing and AI-enabled clinical tools. With no haram business segments, the company passes this screener's business-activity gate.
How much interest-bearing debt does Tempus AI have?
Tempus AI's total interest-bearing debt was $1,360,710 thousand ($1.36 billion) at June 30, 2026, per its Q2 2026 Form 10-Q balance sheet: convertible senior notes, net $1,172,781 thousand and convertible promissory notes $187,929 thousand. The company repaid its $100 million revolving credit facility to zero and retired all other long-term debt in the first half of 2026. Operating lease liabilities ($12,192 thousand current plus $71,266 thousand noncurrent) are excluded - they are not interest-bearing debt. $1.36 billion against a market capitalization of about $15.35 billion (Finnhub, October 2, 2026) is about 8.9%, well under the 33% ceiling.
How much interest income does Tempus AI earn?
Tempus AI's FY2025 Form 10-K discloses interest income as its own income-statement line: $12,628 thousand in FY2025 (interest earned on cash and cash equivalents). Against FY2025 total net revenue of $1,271,789 thousand, that is about 0.99% - well under the 5% non-compliant income ceiling. (For the first six months of 2026, interest income was $7,763 thousand per the Q2 2026 10-Q.)
What do third-party Shariah screeners say about Tempus AI?
Musaffa publishes a TEM page and rates it not halal as of October 2026 using the AAOIFI methodology, but the page does not state which ratio or criterion drove that classification, so its reasoning cannot be reported here. Zoya publishes a TEM page, but its compliance rating could not be determined from the fetched page - no Zoya rating is invented here. I could not find a ShariaPortfolio TEM page from public sources. Third-party screeners apply different assumptions and update on different schedules, and their results can change when new financial statements are published - always check the latest screening before investing.
Sources
- Tempus AI Q2 2026 Form 10-Q (quarter ended June 30, 2026; SEC EDGAR)
- Tempus AI FY2025 Form 10-K (filed February 24, 2026; SEC-sourced mirror)
- Finnhub - Tempus AI financial market data (market cap ~$15.35B, price)
- Musaffa - Tempus AI (TEM) Shariah compliance page
- Zoya - Tempus AI (TEM) stock page
Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).